Competitive AdvantagePEDMARK has unique IP protection until 2039 and orphan drug status until 2029, providing a competitive advantage.
European CommercializationFennec's product under the trade name PEDMARQSI® is expected to advance European commercialization under Norgine, opening up new market opportunities.
Market ExpansionFennec Pharmaceuticals is poised to benefit from market expansion to the adolescent and young adult community with payor reimbursement and product adoption within prominent academic centers.